STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.

Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 02/2012; 109(8):2860-5. DOI: 10.1073/pnas.1120589109
Source: PubMed

ABSTRACT Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS. Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with small molecules has yet to be demonstrated. Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent cancer cells were proposed to have a unique requirement for the serine/threonine kinase STK33. Thus, it was suggested that small-molecule inhibitors of STK33 might have therapeutic benefit in these cancers. Here, we describe the development of selective, low nanomolar inhibitors of STK33's kinase activity. The most potent and selective of these, BRD8899, failed to kill KRAS-dependent cells. While several explanations for this result exist, our data are most consistent with the view that inhibition of STK33's kinase activity does not represent a promising anti-KRAS therapeutic strategy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Activating KRAS mutations are detected in a substantial number of hematologic malignancies. In a murine T-ALL model, we have previously shown that expression of oncogenic Kras induced a premalignant state accompanied with an arrest in T-cell differentiation and acquisition of somatic Notch1 mutations. These findings prompted us to investigate whether the expression of oncogenic KRAS directly affects DNA damage repair. Applying divergent, but complementary genetic approaches, we demonstrate that the expression of KRAS-mutants is associated with increased expression of DNA ligase 3α, PARP1 and XRCC1, all essential components of the error-prone, alternative non-homologous end-joining (alt-NHEJ) pathway. Functional studies revealed delayed repair kinetics, increased misrepair of DNA double-strand breaks and the preferential use of microhomologous DNA sequences for end-joining. Similar effects were observed in primary murine T-ALL blasts. We further show that KRAS-mutated cells, but not KRAS-wild-type cells, rely on the alt-NHEJ repair pathway upon genotoxic stress. RNAi-mediated "knockdown" of DNA ligase 3α abolished resistance to apoptotic cell death in KRAS-mutated cells. Our data indicate that targeting components of the alt-NHEJ pathway sensitizes KRAS-mutated leukemic cells to standard chemotherapeutics and represents a promising approach for inducing synthetic lethal vulnerability in cells harboring otherwise non-druggable KRAS mutations.
    Blood 02/2014; · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oncogenic KRAS mutation is the signature genetic event in the progression and growth of pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease. Although it has been appreciated for some time that nearly 95% of PDAC harbor mutationally activated KRAS, to date no effective treatments that target this mutant protein have reached the clinic. A number of studies have shown that oncogenic KRAS plays a central role in controlling tumor metabolism by orchestrating multiple metabolic changes including stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metabolism, increased autophagy, and macropinocytosis. We review these recent findings and address how they may be applied to develop new PDAC treatments.
    Trends in Biochemical Sciences 01/2014; · 13.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intrinsic or acquired drug resistance often limits the success of cancer treatment. Loss of function genetic screens can help identify mechanisms of drug resistance and thereby deliver strategies to combat resistance. A further application of these genetic screens is the identification of drug targets whose inactivation is only effective in a specific context. This synthetic lethality approach enables the identification of drugs that act only in cancer cells having a cancer-specific mutation and the discovery of potent combination therapies. This review focuses on the question how functional genetic screens can help to improve the treatment of cancer.
    Current opinion in genetics & development 12/2013; 24C:23-29. · 8.99 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014